Eli Lilly on Tuesday raised its full-year profit forecast, betting on surging demand for its weight-loss treatment Zepbound ...
Explosive demand and increased manufacturing capacity for Eli Lilly's weight-loss drug Zepbound drove the company to raise ...
(Reuters) -Eli Lilly on Tuesday raised its full-year profit forecast, betting on surging demand for its weight-loss treatment Zepbound and type 2 diabetes drug Mounjaro. Shares of the company rose ...
Explosive demand and increased manufacturing capacity for Eli Lilly's weight-loss drug Zepbound drove the company to raise ...
Eli Lilly and Company (LLY) raised its outlook for 2024 on rapidly climbing sales of the new obesity drug Zepbound and its ...
(Reuters) -Explosive demand and increased manufacturing capacity for Eli Lilly (NYSE: LLY )'s weight-loss drug Zepbound drove the ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial ...